Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2017

Open Access 01.12.2017 | Research article

Decreased cardiac mortality with nicorandil in patients with ischemic heart failure

verfasst von: Akiomi Yoshihisa, Yu Sato, Shunsuke Watanabe, Tetsuro Yokokawa, Takamasa Sato, Satoshi Suzuki, Masayoshi Oikawa, Atsushi Kobayashi, Yasuchika Takeishi

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2017

Abstract

Background

Effective treatments in heart failure (HF) patients with ischemic etiology have not been fully established. Nicorandil, combination of nitrate component and sarcolemmal adenosine triphosphate-sensitive potassium channel opener, is a potent vasodilator of coronary and peripheral vessels and has been used as an antianginal agent. Therefore, we examined impacts of nicorandil on cardiac mortality in ischemic HF patients.

Methods

Consecutive 334 HF patients with ischemic etiology were retrospectively registered and divided into 2 groups based on oral administration of nicorandil: nicorandil group (n = 116) and non-nicorandil group (n = 218). We retrospectively examined cardiac mortality.

Results

In the Kaplan-Meier analysis (mean follow-up period 963 days), cardiac mortality was significantly lower in the nicorandil group than in the non-nicorandil group (11.2% vs. 19.7%, P = 0.032). In the Cox proportional hazard analysis, usage of nicorandil was a suppressor of cardiac mortality (hazard ratio 0.512, 95% confidence interval 0.275–0.953, P = 0.035), and this result was consistent in several subgroup analyses, such as left ventricular ejection fraction, percutaneous coronary intervention, coronary artery bypass graft, diabetes, β-blockers, and statins.

Conclusion

Nicorandil is potentially effective for reducing mortality in patients with ischemic heart failure.

Trial registration

This was a retrospective study.
Abkürzungen
CABG
Coronary artery bypass graft
CI
Confidence interval
HF
Heart failure
HR
Hazard ratio
LVEF
Left ventricular ejection fraction
RR
Relative risk

Background

Recent standard pharmacotherapy for heart failure (HF), such as beta-blockers and renin angiotensin system inhibitors, have much improved mortality in HF patients [13]. HF with ischemic etiology accounts for more than 50% of HF cases in Europe and North America, as well as 30–40% of HF cases in East Asia, and Latin America and the Caribbean [4]. Ischemic HF is associated with shorter survival than non-ischemic HF [5]. Percutaneous coronary intervention and mitral valve repair, except for coronary artery bypass graft (CABG), do not sufficiently improve the cardiac mortality rate in ischemic HF patients [69]. It has been recently reported that CABG added to pharmacotherapy decreases cardiovascular mortality as 10-year outcome [10]. A more comprehensive approach is necessary to refocus preventive and therapeutic strategies, and to decrease ischemic HF morbidity and mortality. Nicorandil, a combination of nitrate components and sarcolemmal adenosine triphosphate-sensitive potassium channel opener, is a potent vasodilator of coronary and peripheral vessels and has been used as an antianginal agent [11]. A recent meta-analysis revealed that nicorandil treatment in patients with ischemic heart disease did not reduce revascularization (relative risk, RR 0.95, 95% CI 0.70–1.29) or all-cause mortality (RR 0.81, 95% CI 0.64–1.02), but did reduce cardiovascular events (RR 0.77, 95% CI 0.69–0.86) [11]. Therefore, we examined the impacts of oral administration of nicorandil on cardiac mortality in ischemic HF patients.

Methods

Subjects and study protocol

This was a retrospective study. Consecutive 334 HF patients with ischemic etiology at Fukushima Medical University between 2009 and 2014 were divided into two groups based on oral administration of nicorandil at hospital discharge: a nicorandil group (guideline-based medical therapy + nicorandil 5 mg tid, n = 116) and non-nicorandil group (guideline-based medical therapy alone, n = 218). While the prescription of nicorandil was determined by the attending physician freely, patients with advanced coronary artery disease tended to be prescribed nicorandil in our hospital. Diagnosis of decompensated HF was defined based on the Framingham criteria [12]. Ischemic etiology was confirmed by either myocardial scintigraphy or coronary computed tomography angiography and/or coronary angiography. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the institution’s human research committee. We compared clinical features between the two groups. All patients were followed up for cardiac death until 2016. Cardiac death was adjudicated by independent experienced cardiologists and included death due to worsened HF in accordance with the Framingham criteria [12], ventricular fibrillation documented by electrocardiogram or other implantable devices, and acute coronary syndrome.

Statistical analysis

The chi-square test was used for comparisons of categorical variables. Data of the two groups were compared using the independent Student’s t-test for normally distributed data, and the Mann-Whitney U test for non-normally distributed data. To assess the potential heterogeneity of nicorandil treatment effects on cardiac mortality, we conducted subgroup analyses. Interactions between nicorandil and the following clinically relevant variables, which are different between the two groups and/or generally known risk factors, were estimated by a Cox proportional hazards regression model: age, sex, left ventricular ejection fraction (LVEF), presence of left main trunk lesion, three-vessel disease, history of percutaneous coronary intervention or CABG, presence of diabetes, chronic kidney disease, dialysis, and use of β-blockers, statins, anti-platelet agents, and nitrate. A value of P < 0.05 was considered statistically significant for all comparisons. Analyses were performed using a statistical software package (SPSS ver. 21.0, IBM, Armonk, NY, USA).

Results

As shown in Table 1, the nicorandil group had higher prevalence of three-vessel disease, history of coronary artery bypass graft, usage of anti-platelet agents and statins, and tended to have higher prevalence of diabetes and usage of β-blockers and nitrates. In contrast, age, gender, New York Heart Association class, other co-morbidities, B-type natriuretic peptide, C-reactive protein, total protein, sodium, and LVEF did not differ between the two groups. During the follow-up period (mean 963 days), there were 56 cardiac deaths (13 in the nicorandil group and 43 in the non-nicorandil group). As shown in Fig. 1, the cardiac mortality was significantly lower in the nicorandil group than in the non-nicorandil group (P = 0.032). In the Cox proportional hazard analysis (Table 2), usage of nicorandil was a suppressor of cardiac mortality (HR 0.512, 95%CI 0.275–0.953, P = 0.035). Interactions between nicorandil use and clinically relevant variables were modeled using Cox regression and are shown in Table 2 for cardiac mortality. In the subgroup analysis, there was no interaction between nicorandil use and other important variables that affect cardiac mortality in any subgroups. Then, we focused on the history of CABG (Fig. 2), cardiac mortality was significantly lower in the nicorandil group than in the non-nicorandil group in patients with CABG (P = 0.019), and remained in a tendency in patients without CABG (P = 0.133).
Table 1
Comparisons of clinical features (N = 334)
 
Non-nicorandil group
(n = 218)
Nicorandil group
(n = 116)
P-value
Age (years)
71.7 ± 11.6
69.8 ± 10.5
0.146
Male gender (n, %)
169 (77.5)
86 (74.1)
0.488
Body mass index (kg/cm2)
23.7 ± 4.6
23.9 ± 4.2
0.708
Systolic blood pressure (mmHg)
132.3 ± 36.1
130.8 ± 35.9
0.716
Diastolic blood pressure (mmHg)
76.2 ± 23.3
72.4 ± 21.5
0.144
Heart rate (bpm)
82.2 ± 23.8
77.5 ± 21.2
0.071
New York Heart Association class III or IV (n, %)
5 (2.3)
3 (2.6)
0.868
LVEF (%)
43.3 ± 13.6
45.6 ± 14.5
0.211
LMT lesion (n, %)
9 (4.1)
10 (8.6)
0.134
3VD (n, %)
45 (20.6)
40 (34.5)
0.008
PCI (n, %)
159 (72.9)
86 (74.1)
0.813
CABG (n, %)
27 (12.4)
42 (36.2)
<0.001
Co-morbidity
 Hypertension (n, %)
194 (89.0)
105 (90.5)
0.665
 Diabetes (n, %)
128 (58.7)
79 (68.1)
0.092
 Dyslipidemia (n, %)
193 (88.5)
107 (92.2)
0.286
 Atrial fibrillation (n, %)
64 (29.4)
27 (23.3)
0.235
 Chronic kidney disease (n, %)
151 (69.3)
78 (67.2)
0.704
 Dialysis (n, %)
28 (12.8)
16 (13.8)
0.865
 Anemia (n, %)
141 (64.7)
78 (67.2)
0.639
 Smoking (n, %)
155 (71.1)
74 (63.8)
0.171
Medications
 Angiotensin converting enzyme inhibitors (n, %)
123 (56.4)
71 (61.2)
0.417
 Angiotensin receptor blockers (n, %)
67 (30.7)
36 (31.0)
1.000
 Aldosterone antagonists (n, %)
91 (41.7)
42 (36.2)
0.325
 β-blockers (n, %)
176 (80.7)
102 (87.9)
0.094
 Calcium channel blockers (n, %)
94 (43.1)
47 (40.5)
0.727
 Diuretics (n, %)
153 (70.2)
79 (68.1)
0.694
 Inotropic agents (n, %)
27 (12.4)
11 (9.5)
0.426
 Anti-platelet agents (n, %)
186 (85.3)
113 (97.4)
<0.001
 Anti-coagulations (n, %)
97 (44.5)
50 (43.1)
0.807
 Anti-diabetic agents (n, %)
92 (42.2)
59 (50.9)
0.135
 Statins (n, %)
132 (60.6)
88 (75.9)
0.005
 Nitrates (n, %)
44 (20.2)
34 (29.3)
0.077
Laboratory data
 BNP (pg/ml)a
306.5 (865.1)
377.5 (619.8)
0.374
 C-reactive protein (mg/dl)a
0.32 (1.19)
0.21 (0.78)
0.132
 Total protein (g/dl)
7.0 ± 0.8
7.0 ± 0.7
0.816
 Sodium (mEq/l)
138.2 ± 4.2
138.6 ± 3.5
0.492
LVEF left ventricular ejection fraction, LMT left main trunk, 3VD three-vessel disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, BNP B-type natriuretic peptide
aData are presented as median (interquartile range)
Table 2
Subgroup analysis for cardiac mortality: Nicorandil use
Factor
Subgroup
n
HR
95% Cl
P value
Interaction P value
Total
 
334
0.512
0.275–0.953
0.035
-
Age
≥75
143
0.807
0.344–1.890
0.621
0.252
<75
191
0.380
0.153–0.942
0.037
Sex
Male
255
0.449
0.216–0.932
0.032
0.403
Female
79
0.737
0.213–2.547
0.629
LVEF
Reduced
244
0.623
0.325–1.192
0.153
0.405
Preserved
90
0.245
0.029–2.102
0.200
LMT
Present
19
1.240
0.000–3.420
0.581
0.968
Absent
315
0.492
0.259–0.934
0.030
3VD
Present
85
0.672
0.244–1.849
0.441
0.482
Absent
249
0.425
0.188–0.962
0.040
PCI
Present
245
0.556
0.272–1.138
0.108
0.646
Absent
89
0.422
0.120–1.483
0.179
CABG
Present
69
0.181
0.036–0.897
0.036
0.128
Absent
265
0.718
0.366–1.409
0.336
Diabetes
Present
207
0.412
0.177–0.957
0.039
0.361
Absent
127
0.742
0.296–1.858
0.523
CKD
Present
229
0.434
0.217–0.871
0.019
0.206
Absent
105
1.252
0.280–5.596
0.769
Dialysis
Present
44
0.338
0.073–1.568
0.166
0.595
Absent
290
0.557
0.282–1.100
0.092
β-blockers
Present
278
0.483
0.229–1.022
0.057
0.469
Absent
56
0.830
0.273–2.523
0.743
Statins
Present
220
0.720
0.324–1.604
0.422
0.425
Absent
114
0.400
0.139–1.153
0.090
Anti-platelet agents
Present
299
0.600
0.316–1.140
0.119
0.907
Absent
35
0.041
0.000–215.058
0.464
Nitrates
Present
78
0.551
0.188–1.616
0.277
0.814
Absent
256
0.474
0.219–1.027
0.058
LVEF left ventricular ejection fraction, LMT left main trunk, 3VD three-vessel disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CKD chronic kidney disease

Discussion

In the present study, we firstly demonstrated that oral administration of nicorandil was associated with lower cardiac mortality in ischemic HF patients, and this result was consistent in several subgroup analyses, such as LVEF, percutaneous coronary intervention, coronary artery bypass graft, diabetes, β-blockers, and statins.
Intravenous nicorandil for decompensated HF patients, regardless of ischemic etiology, improves cardiac pump function, New York Heart Association class, left ventricular function, myocardial microvascular circulation, pulmonary capillary wedge pressure, pulmonary arterial pressure, and peripheral resistance [13], and oral administration of nicorandil decreases the composite end point of mortality and hospitalization for cardiac causes (HR 0.35, 95% CI 0.16–0.54) [13]. Oral administration of nicorandil suppresses sympathetic nervous activity, prevents left ventricular remodeling in HF patients (LVEF <45%, ischemic etiology 43.5%), and may reduce cardiac events (cardiac mortality, HR 0.502, 95% CI 0.268–0.940; major adverse cardiac effect, HR 0.436, 95% CI 0.266–0.715) [14]. These previous reports [13, 14] are partially concordant with our results.
Several favorable effects of nicorandil on cardiovascular system have been reported, such as reduction in preload and afterload, improvement of myocardial perfusion, protection of cardiomyocytes from ischemic damage, prevention of Ca2+ overload by opening adenosine triphosphate-sensitive potassium channels, anti-inflammatory and anti-proliferative effects, anti-apoptosis, anti-arrhythmic effects, protection of endothelial, mitochondrial, and energy-modulating functions, and preservation of kidney function [11, 13, 14].

Study limitations

There are several limitations in the present study. First, it is a nonrandomized and retrospective study of a single institution, so the number of subjects was relatively small and there are potential biases and confounders that may be responsible for our findings. Second, we have conducted this study using only variables on hospitalization, without consideration for changes in medical parameters and post-discharge treatment. Third, our results has not established a cause-effect relationship between the usage of nicorandil and improvement of cardiac mortality. Thus, the results of the present study should be viewed as preliminary, and further studies with larger populations and randomization are needed.

Conclusions

In conclusion, nicorandil potentially reduces cardiovascular mortality in patients with ischemic HF.

Acknowledgements

The authors acknowledge Ms. Kumiko Watanabe, Ms. Tomiko Miura and Ms. Hitomi Kobayashi for their outstanding technical assistance.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

AY and YT, making article, drafting the article and conception of this study; SW and TY, performing statistical analysis; TS, SS, MO, and AK obtaining general data; YT revising the article critically for important intellectual content. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.
Not applicable.
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the institution’s human research committee (Fukushima Medical University).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRefPubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRefPubMed
2.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMed
3.
Zurück zum Zitat Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Liu Y, Mehra MR, et al. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J Am Heart Assoc. 2012;1(1):16–26.CrossRefPubMedPubMedCentral Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Liu Y, Mehra MR, et al. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J Am Heart Assoc. 2012;1(1):16–26.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol. 2013;168(2):1186–94.CrossRefPubMed Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol. 2013;168(2):1186–94.CrossRefPubMed
5.
Zurück zum Zitat Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39(2):210–8.CrossRefPubMed Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39(2):210–8.CrossRefPubMed
6.
Zurück zum Zitat Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014;371(23):2178–88.CrossRefPubMedPubMedCentral Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014;371(23):2178–88.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–38.CrossRefPubMed Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–38.CrossRefPubMed
8.
Zurück zum Zitat Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation. 2012;125(21):2639–48.CrossRefPubMedPubMedCentral Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation. 2012;125(21):2639–48.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–16.CrossRefPubMedPubMedCentral Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–16.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, et al. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134(18):1314–24.CrossRefPubMed Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, et al. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134(18):1314–24.CrossRefPubMed
11.
Zurück zum Zitat Luo B, Wu P, Bu T, Zeng Z, Lu D. All-cause mortality and cardiovascular events with nicorandil in patients with IHD: systematic review and meta-analysis of the literature. Int J Cardiol. 2014;176(3):661–9.CrossRefPubMed Luo B, Wu P, Bu T, Zeng Z, Lu D. All-cause mortality and cardiovascular events with nicorandil in patients with IHD: systematic review and meta-analysis of the literature. Int J Cardiol. 2014;176(3):661–9.CrossRefPubMed
12.
Zurück zum Zitat McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441–6.CrossRefPubMed McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441–6.CrossRefPubMed
13.
Zurück zum Zitat Zhao F, Chaugai S, Chen P, Wang Y, Wang DW. Effect of nicorandil in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Ther. 2014;32(6):283–96.CrossRefPubMed Zhao F, Chaugai S, Chen P, Wang Y, Wang DW. Effect of nicorandil in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Ther. 2014;32(6):283–96.CrossRefPubMed
14.
Zurück zum Zitat Kasama S, Toyama T, Iwasaki T, Sumino H, Kumakura H, Minami K, et al. Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching. Eur J Nucl Med Mol Imaging. 2014;41(1):144–54.CrossRefPubMed Kasama S, Toyama T, Iwasaki T, Sumino H, Kumakura H, Minami K, et al. Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching. Eur J Nucl Med Mol Imaging. 2014;41(1):144–54.CrossRefPubMed
Metadaten
Titel
Decreased cardiac mortality with nicorandil in patients with ischemic heart failure
verfasst von
Akiomi Yoshihisa
Yu Sato
Shunsuke Watanabe
Tetsuro Yokokawa
Takamasa Sato
Satoshi Suzuki
Masayoshi Oikawa
Atsushi Kobayashi
Yasuchika Takeishi
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2017
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-017-0577-3

Weitere Artikel der Ausgabe 1/2017

BMC Cardiovascular Disorders 1/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.